Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 19.01 as of 2026-09-12T00:16:11.359Z.
Consensus retrieved: 2026-09-10T03:53:40.827Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-12T00:16:11.359Z.
Quote observation: 2026-09-11T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d1f0a601bf4881217105f3d38e84d63c1bd62d476e1a552230e61949490821d6
Forward PE Ratio (19.01) = Dated Quote Price ($497.11) / Consensus Forward EPS ($26.15)
FORWARD PE RATIO
19.01
SECTOR MEDIAN · HEALTHCARE
18.95
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
+0.29%
vs the sector median at left
United Therapeutics Corporation
Market Cap
$21.10B
Forward PE Ratio
19.01
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| United Therapeutics Corporation (UTHR) | $21.10B | 19.01 |
| STERIS plc (STE)vs › | $20.54B | 18.81 |
| Viatris Inc. (VTRS)vs › | $19.23B | 6.60 |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.09B | 10.96 |
| BioNTech SE (BNTX)vs › | $24.30B | N/A |
| West Pharmaceutical Services, Inc. (WST)vs › | $24.37B | 38.61 |
| Incyte Corporation (INCY)vs › | $24.62B | 32.29 |
| Labcorp Holdings Inc. (LH)vs › | $25.55B | 16.98 |
| Medpace Holdings, Inc. (MEDP)vs › | $16.40B | 33.38 |
| Quest Diagnostics Incorporated (DGX)vs › | $25.94B | 21.00 |
Trailing P/E
17.8
reported TTM EPS
Forward P/E
19.0
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $26.15 implies -6.3% EPS decline vs the reported trailing $27.91.
At the dated quote price of $497.11, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $26.15 | $23.74 – $27.31 | 11 | 19.0x |
| 2027-12-31 | $28.90 | $23.09 – $35.16 | 11 | 17.2x |
| 2028-12-31 | $34.67 | $23.30 – $46.90 | 10 | 14.3x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
